Convergent Therapeutics, Inc.
Philip Kantoff is currently the Co-Founder and Chief Executive Officer of Convergent Therapeutics, Inc., a position held since July 2021. Throughout their esteemed career, Philip has served as the Jerome and Nancy Kohlberg Professor Emeritus at Harvard Medical School since November 2015, while also contributing as a board member for the Prostate Cancer Foundation, ESSA Pharma, and Context Therapeutics. Previously, Philip held the role of Chairman of Medicine at Memorial Sloan Kettering Cancer Center from November 2015 to June 2021 and was the Division Head for Solid Tumor Oncology at Dana-Farber Cancer Institute from January 1991 to November 2015. Philip Kantoff earned a Doctor of Medicine (MD) degree in Medical Oncology from The Warren Alpert Medical School of Brown University.
This person is not in any teams
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.